Cherchez une société par raison sociale, ticker ou ISIN, puis ouvrez sa fiche.
Performance
Sur 100 ¥ facturés en 2024, 42 ¥ partent en coût des ventes, 22 ¥ en frais d’exploitation et 5 ¥ en impôts, intérêts et divers. Il reste 31 ¥ de bénéfice net.
Le nombre d’actions est passé de 222,1 M à 263,5 M entre 2021 et 2025, soit 18,7 % de titres en plus : le bénéfice se partage entre davantage de parts.
Beijing Scitop Bio-tech Co., Ltd. engages in the research, development, production, and sale of probiotic, postbiotics, and microecological preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. The company also offers microecological preparations and related application technologies for ruminants, monogastric livestock and poultry animals, aquatic animals, and pets. In addition, it develops and promotes microbial agents, such as microbial fertilizers, bio-organic fertilizers, organic material decomposition agents, etc. for vegetable, fruit, edible fungus, forage grass, and crop planting. Beijing Scitop Bio-tech Co., Ltd. was founded in 2003 and is headquartered in Beijing, China.
En 2025, l’entreprise a comptabilisé 94,5 M CNY de bénéfice et laissé -172,7 M CNY en caisse une fois l’exploitation payée et les investissements faits, soit -183 ¥ de trésorerie pour 100 ¥ de bénéfice.